Andreas Argyrides
Stock Analyst at Oppenheimer
(4.48)
# 716
Out of 4,479 analysts
90
Total ratings
56.45%
Success rate
18.26%
Average return
Main Sectors:
Top Industries:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Initiates: Perform | n/a | $12.04 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $41.80 | +148.80% | 14 | Jun 25, 2024 | |
| KROS Keros Therapeutics | Initiates: Outperform | $102 | $43.77 | +133.04% | 5 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $1.24 | +303.23% | 1 | Jun 25, 2024 | |
| GOSS Gossamer Bio | Initiates: Outperform | $9 | $0.95 | +849.77% | 8 | Jun 25, 2024 | |
| SPRY ARS Pharmaceuticals | Reiterates: Outperform | $19 | $8.73 | +117.64% | 9 | Mar 11, 2024 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $4 → $9 | $2.45 | +267.35% | 4 | Mar 7, 2024 | |
| OCS Oculis Holding AG | Reiterates: Outperform | $29 | $11.89 | +143.90% | 3 | Mar 6, 2024 | |
| RGNX REGENXBIO | Reiterates: Neutral | $21 | $11.07 | +89.70% | 4 | Feb 28, 2024 | |
| SRPT Sarepta Therapeutics | Reiterates: Outperform | $224 | $156.75 | +42.90% | 4 | Feb 20, 2024 | |
| PCRX Pacira BioSciences | Reiterates: Outperform | $57 | $28.46 | +100.28% | 2 | Feb 8, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $207 → $225 | $133.98 | +67.94% | 8 | Feb 8, 2024 | |
| RANI Rani Therapeutics Holdings | Reiterates: Outperform | $8 | $3.82 | +109.42% | 3 | Feb 6, 2024 | |
| UBX Unity Biotechnology | Upgrades: Outperform | n/a | $1.33 | - | 6 | Nov 16, 2023 | |
| IMUX Immunic | Maintains: Outperform | $5 → $7 | $1.12 | +525.00% | 3 | Oct 10, 2023 | |
| MNKD MannKind | Initiates: Outperform | $10 | $5.09 | +96.46% | 1 | Oct 10, 2023 | |
| SGMO Sangamo Therapeutics | Maintains: Outperform | $16 → $10 | $0.33 | +2,930.30% | 3 | Aug 11, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $73 → $70 | $82.13 | -14.77% | 6 | Aug 1, 2023 |
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $12.04
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $41.80
Upside: +148.80%
Keros Therapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $102
Current: $43.77
Upside: +133.04%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $1.24
Upside: +303.23%
Gossamer Bio
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $0.95
Upside: +849.77%
ARS Pharmaceuticals
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $8.73
Upside: +117.64%
Aquestive Therapeutics
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $2.45
Upside: +267.35%
Oculis Holding AG
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $11.89
Upside: +143.90%
REGENXBIO
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $11.07
Upside: +89.70%
Sarepta Therapeutics
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $156.75
Upside: +42.90%
Pacira BioSciences
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $28.46
Upside: +100.28%
Ascendis Pharma
Feb 8, 2024
Maintains: Outperform
Price Target: $207 → $225
Current: $133.98
Upside: +67.94%
Rani Therapeutics Holdings
Feb 6, 2024
Reiterates: Outperform
Price Target: $8
Current: $3.82
Upside: +109.42%
Unity Biotechnology
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.33
Upside: -
Immunic
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.12
Upside: +525.00%
MannKind
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $5.09
Upside: +96.46%
Sangamo Therapeutics
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.33
Upside: +2,930.30%
BioMarin Pharmaceutical
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $82.13
Upside: -14.77%